ÑòÍÕVHH SingleB?¿ìËÙ·¢ÏÖ

ÑòÍÕµÈÂæÍտƶ¯ÎïÌåÄÚÌìÈ»´æÔÚȱʧÇáÁ´¼°ÖØÁ´CH1½á¹¹µ«ÍêÈ«±£Áô¿¹Ô­½áºÏ»îÐÔµÄÖØÁ´¿¹Ì壨HCAb£©£¬ÆäÖÐÌØÒìÐÔ½áºÏ¿¹Ô­µÄÖØÁ´¿É±äÇø³ÆÎªµ¥Óò¿¹Ì壨sdAbs£©£¬¼´ÄÉÃ׿¹Ì壨Nanobody£©£¬¼ò³ÆVHH£¬ÊÇ×îСµ¥Ôª¿¹Ô­½áºÏƬ¶Î¡£

µÂÌ©ÉúÎï»ùÓÚÁ÷ʽϸ°û·Öѡƽ̨ºÍDeepLight?ɸѡƽ̨£¬ÌṩÑòÍÕVHH SingleB?¿ìËÙÖÆ±¸·þÎñ£¬´ÓÑòÍÕÃâÒß¡¢¼ÇÒäBϸ°ûºÍ½¬Ï¸°û˫ɸѡ¡¢BGE?¸ßͨÁ¿±í´ï¡¢±í´ï¼ø¶¨µ½´¿»¯£¬È«Á÷³Ì½öÐè90Ìì¡£

VHH¶ÀÌØÓÅÊÆ

Conventional antibody

Conventional antibody
150kDa

Camelid heavy-chain antibody

Camelid heavy-chain antibody
95kDa

Fv

Fv
30kDa
scFv
30kDa
dsFv
30kDa

Nanobody

Nanobody
12-14kDa

VHH»ùÓÚ½á¹¹ÌØÒìÐÔ£¬¼¯´«Í³¿¹ÌåÓëС·Ö×ÓÒ©ÎïµÄÓŵãΪһÌ壺

  • µÍ·Ö×ÓÁ¿£º½öΪ12-14kDa£¬×éÖ¯´©Í¸Á¦Ç¿£¬¹ã·ºÓ¦ÓÃÓÚÖ×ÁöÕï¶ÏÖÎÁƺͷÖ×ÓÓ°ÏñµÈ¡£
  • ½á¹¹¼òµ¥£ºÒ×ÓÚ½øÐлùÒò¹¤³Ì¸ÄÔ죬ÓëÈËVHͬԴÐÔ80%£¬Ò×ÈËÔ´»¯¡£
  • ÃâÒßÔ­ÐԵͣº²»º¬Fcβ¶Ë£¬²»»áÒý·¢Ïà¹ØµÄÃâÒßÔ­ÐÔ£¬³ÉÒ©ÐԸߡ£
  • ÌØÒìÐԸߣºCDR3Çø½Ï³¤£¬¿ÉÐγÉָ״͹»·½øÒ»²½Ê¶±ðÒþ²Ø¿¹Ô­±íλ¡£
  • ¸ßÇ×Ë®ÐÔ£ºFR2ÇøÇ×Ë®°±»ùËᱣ֤ˮÈÜÐÔ£¬¿¹Ìå²»Ò×¾Û¼¯¡£
  • ÖÆ±¸¼òµ¥£º¿É´óÁ¿±í´ï£¬¹¤Òµ»¯·Å´óÉú²ú³É±¾µÍÖÜÆÚ¶Ì¡£
  • ¸ßÎȶ¨ÐÔ£ºÒ×´¢´æ£¬¿ÉÄÍÊܸßΡ¢Ç¿Ëᡢǿ¼îµÈÖ±äÐÔÌõ¼þ¡£

·þÎñÓÅÊÆ

90Ìì¸ß½»¸¶

90Ìì¸ß½»¸¶

½»¸¶50ÖêFACS binder
¼°VHHÐòÁÐ

¡°1+1¡±Ë«±£ÕÏ

¡°1+1¡±Ë«±£ÕÏ

¼ÇÒäBϸ°û&½¬Ï¸°û
˫ɸѡ˫±£ÕÏ

ǰÖù¦ÄÜɸѡ

ǰÖù¦ÄÜɸѡ

DeepLight?ƽ̨
ʵÏÖ¶àÖÖon-chip assay

ÌìÈ»³ÉÊì

ÌìÈ»³ÉÊì

¿¹ÌåÇ׺ÍÁ¦¸ü¸ß
»ù±¾Ïû³ýÃâÒßÔ­ÐÔ

·þÎñÁ÷³Ì

·þÎñÁ÷³Ì

·þÎñÄÚÈÝ

½×¶Î ·þÎñÄÚÈÝ ÖÜÆÚ ½»¸¶
½×¶Î¢ñ ¶¯ÎïÃâÒß
  • ¿¹Ô­ÖƱ¸£¨¿ÉÑ¡£©
  • ÑòÍÕÃâÒß
  • Ч¼Û¼ì²â
8~9ÖÜ Premium Package

  • ´óÓÚ50ÖêFACS binder
  • ±£ÕÏÐòÁжàÑùÐÔ
  • VHHÐòÁм°±í´ïÖÊÁ£
  • ÖÊÁ¿¼ìÑ鱨¸æ£¨CoA£©

Economic Package

  • 5-10ÖêELISAÑôÐÔ¿Ë¡
  • VHHÐòÁм°±í´ïÖÊÁ£
  • Ñ¡1Öê´¿»¯1mg¿¹Ìå
  • ÖÊÁ¿¼ìÑ鱨¸æ£¨CoA£©
½×¶Î¢ò ¡°1+1¡±Ë«É¸Ñ¡
  • ¼ÇÒäBϸ°ûɸѡ
  • ½¬Ï¸°ûɸѡ
1Ìì
½×¶Î¢ó BGE?¸ßͨÁ¿±í´ï¼°¹¦ÄÜÑéÖ¤
  • ELISA Assay
  • FACS Assay
1~2ÖÜ
½×¶Î¢ô ÄÉÃ׿¹Ìå»ùÒò²âÐò
  • ¸ßͨÁ¿»ùÒò²âÐò
1ÖÜ
½×¶Î¢õ ÖØ×鿹Ìå±í´ïÓë´¿»¯£¨¿ÉÑ¡£©
  • תȾ¼¶ÖÊÁ£ÖƱ¸
  • ˲ʱתȾ±í´ï
  • ¸ßͨÁ¿´¿»¯
  • ÎÞÄÚ¶¾ËØ´¿»¯
Ïêѯ

·þÎñ°¸Àý

FACS sorting of MBCs
Fig 1. FACS sorting of MBCs

FACS binding assay
Fig 2. FACS binding assay

The obtained VHHs in one plate were tested by FACS assay and showed high affinity to antigen and high positive rate.

Ïà¹Ø·þÎñ

¼¼Êõ·þÎñ

  • Ê󵥿¹SingleB?¿ìËÙ·¢ÏÖ
  • Íõ¥¿¹SingleB?¿ìËÙ·¢ÏÖ
  • ÑòÍÕVHH SingleB?¿ìËÙ·¢ÏÖ
  • È«ÈËÔ´Ê󵥿¹SingleB?¿ìËÙ·¢ÏÖ
  • ÔÓ½»Áö¿¹Ìå»ùÒò²âÐò
  • ²¸È鶯Îïϸ°û˲ʱ±í´ï
  • Ô­ºËµ°°×±í´ï
  • ¿¹Ìå¸ßͨÁ¿±í´ï
  • Éú²úÐÍÎÈתϸ°ûÖê¹¹½¨
  • ¿¹ÌåÈËÔ´»¯
ad

Á¢¿Ìѯ¼Û

  • ÐÕÃû

  • ÁªÏµµç»°

  • ×ÉѯÏîÄ¿

  • ÑéÖ¤Âë

  • ÏîÄ¿ÃèÊö

Á¢¼´Ñ¯¼Û
  • ÐÕÃû

  • µ¥Î»

  • µç»°

  • ×ÉѯÏîÄ¿

  • ÑéÖ¤Âë

  • ÁôÑÔ:

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿